It may be time for investors to jump into little-known biotech stock Fulcrum Therapeutics, according to Goldman Sachs.
from International: Top News And Analysis https://ift.tt/aZ6LnmV
via IFTTT
Tuesday, November 15, 2022
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment